Program
ravulizumab
Also written as “Ravulizumab”, “ALXN1210” and “ALXN1210 SC”.
Its studies are mostly in Hemoglobinuria, Paroxysmal · Myasthenia Gravis · Thrombotic Microangiopathies · Neuromyelitis Optica · Atypical Hemolytic Uremic Syndrome, led by 2 companies.
Drug pageRavulizumab: every studyAll 39 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZenecaits history only | 349 open or running | phase 4since Mar 23, 2020 | Nov 2, 2015 | Jun 25, 2027phase 4 · NCT07308574 |
| Regeneron Pharmaceuticals | 10 open or running | phase 3since Nov 12, 2021 | Nov 12, 2021 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Regeneron Pharmaceuticals only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jun 9, 2017Named ravulizumabINNProposed as its International Nonproprietary Name in WHO's List 117 · before, ALXN1210
- Nov 12, 2021First study: phase 3 study in Hemoglobinuria, ParoxysmalFirst studyNCT05131204 · 3 enrolled · United States
TargetBeta
“Complement C5 inhibitor”ChEMBL 37, by rule
Other programs on C5
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| eculizumabrule | AstraZeneca | phase 4 | 38 |
| pozelimabrule | Regeneron Pharmaceuticals | phase 4 | 14 |
| zilucoplanrule | UCB | phase 3 | 14 |
| vilobelimabrule | inflarx-gmbh | phase 3 | 13 |
| Crovalimabrule | Hoffmann-La Roche | phase 3 | 10 |
| cemdisiranrule | Regeneron Pharmaceuticals | phase 3 | 10 |
| ABBV-6628 | AbbVie | phase 2 | 1 |
Studies
The one study Regeneron Pharmaceuticals leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05131204Hemoglobinuria, Paroxysmal · United States | 3 | Terminated | Jul 12, 2023 | 3 |
How it is read
Names in the registry
- “Ravulizumab”, 30 entries
- “ALXN1210”, 4 entries
- “ALXN1210 SC”, 1 entry
- “ALXN1210 IV”, 1 entry
Conditions, from the studies’ own filings
- Hemoglobinuria, Paroxysmal, 9 studies
- Myasthenia Gravis, 4 studies
- Thrombotic Microangiopathies, 3 studies
- Neuromyelitis Optica, 3 studies
- Atypical Hemolytic Uremic Syndrome, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.